Drug Trial Radar · NCT03583710
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Aug 20, 2018
Primary completion
Jan 1, 2029
Study completion Jan 1, 2029
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jul 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial studies how well mitotane alone works compared to mitotane with cisplatin and etoposide when given after surgery in treating patients with adrenocortical cancer that has a high risk of coming back (recurrence). Cortisol can cause the growth of adrenocortical tumor cells. Antihormone therapy, such as mitotane, may lessen the amount of cortisol made by the body. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether mitotane alone or mitotane with cisplatin and etoposide after surgery works better in treating patients with adrenocortical carcinoma.
Conditions
- ENSAT Stage I Adrenal Cortex Carcinoma
- ENSAT Stage II Adrenal Cortex Carcinoma
- ENSAT Stage III Adrenal Cortex Carcinoma
Interventions
CisplatinDrug
Given IV
EtoposideDrug
Given IV
MitotaneDrug
Given PO
Quality-of-Life AssessmentOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence-free survival (RFS)Time frame: From the time of randomization up to 2 years
- Local recurrence of adrenocortical carcinoma (ACC)Time frame: Up to 6 months
- Distant recurrence of ACCTime frame: Up to 6 months
Locations
33 sites in 5 countries. Site status is shown where the registry gives one.
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan · Recruiting
Siteman Cancer Center at Washington University
St Louis, Missouri · Active not recruiting
M D Anderson Cancer Center
Houston, Texas · Recruiting
Institut de Cancérologie de l'Ouest (ICO)
Angers, France · Active not recruiting
CHU Angers, Hôpital Larrey
Angers, France · Recruiting
CHU Besançon, Hôpital Jean Minjoz
Besançon, France · Recruiting
CHU Brest, Hôpital La Cavale Blanche
Brest, France · Active not recruiting
Centre Georges François Leclerc
Dijon, France · Recruiting
Lyon HCL
Lyon, France · Recruiting
HCL Hôpital Louis Pradel
Lyon, France · Not yet recruiting
Marseille Hôpital Nord
Marseille, France · Recruiting
Marseille Hôpital de la Conception
Marseille, France · Recruiting
CHU Nantes, Hôpital René et Guillaume Laënnec
Nantes, France · Active not recruiting
CHU Nantes, Hôpital René et Guillaume Laënnec
Nantes, France · Recruiting
Hôpital Cochin, AP-HP
Paris, France · Recruiting
Hôpital Cochin, AP-HP
Paris, France · Active not recruiting
Hôpital Cochin
Paris, France · Recruiting
Hôpital COCHIN
Paris, France · Active not recruiting
CHU Bordeaux - Hôpital Haut Lévèque
Pessac, France · Recruiting
CHU Poitiers
Poitiers, France · Recruiting
CHU Reims
Reims, France · Recruiting
HUS, Hôpital Hautepierre
Strasbourg, France · Not yet recruiting
Strasbourg HUS Hautepierre
Strasbourg, France · Active not recruiting
CHU Toulouse, Hôpital Larrey
Toulouse, France · Recruiting
CHU Toulouse, Hôpital Rangueil
Toulouse, France · Active not recruiting
Gustave Roussy
Villejuif, France · Recruiting
LMU Klinikum München
Munich, Germany · Recruiting
Universitätsklinikum Würzburg
Würzburg, Germany · Recruiting
Maria Sklodowska-Curie National Research Institute of Oncology
Gliwice, Poland · Active not recruiting
Sahlgrenska University Hospital
Gothenburg, Sweden · Recruiting
Skånes Universitetssjukhus
Lund, Sweden · Recruiting
Karolinska University Hospital
Stockholm, Sweden · Recruiting
Akademiska Sjukhuset
Uppsala, Sweden · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.